A double blind randomized crossover phase III study of oral thalidomide versus placebo in patients with stage D0 androgen dependent prostate cancer following limited hormonal ablation.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Gonadotropin releasing hormone stimulants; Goserelin; Leuprorelin; Thalidomide
- Indications Prostate cancer
- Focus Therapeutic Use
- 22 May 2018 Biomarkers information updated
- 11 Sep 2012 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 11 Sep 2012 Additional lead trial centres identified as reported by ClinicalTrials.gov.